FDA Inspection 1067515 — Regeneron Pharmaceuticals Inc
The FDA completed an inspection of Regeneron Pharmaceuticals Inc on August 10, 2018 in Tarrytown, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 10, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Tarrytown, NY (United States)
Additional Details
Postmarket Adverse Drug Experience (PADE)